https://m2.mtmt.hu/ hun 2026-09-23 05:53 JournalArticle 32012570 VALIDATED true 1 false 2026-08-02T18:13:01.046+0000 2025-06-03T14:30:26.772+0000 2021-05-13T07:38:14.219+0000 true 10070835 xSzepesy xJudit /api/admin/10070835 Admin xSzepesy xJudit (xSE_AOK_Farmakol_Admin5_SzJ, admin) true 2025-07-07T12:49:48.516+0000 2025-07-07T12:49:48.516+0000 2022-02-09T09:48:31.060+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 Admin 10003133 /api/admin/10003133 Boros Annamária (MTMT Központi admin) Boros Annamária true 10003133 true 2022-03-25T09:34:12.609+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000359 Study Group true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000359 Sokszerzős vagy csoportos szerzőségű szakcikk SubType Sokszerzős vagy csoportos szerzőségű szakcikk (Folyóiratcikk) 104 true 10000359 true 1 /api/category/1 Category Tudományos true 1 de Guillebon, E. true true /api/journal/10082274 REVIEWED ESMO OPEN 2059-7029 2059-7029 true false 10082274 false 10082274 true 2059-7029 2059-7029 Journal FOREIGN 6 3 100106 100106 12 2021 Funding 2009389 /api/funding/2009389 (ED_18-2-2019-0001) Támogató: NKFIH false true Funding 2009390 /api/funding/2009390 (NVKP_ 16-1-2016-0005) Támogató: NKFIH false true Funding 2009391 /api/funding/2009391 (2019-1.1.1-PIACI-KFI-2019-00367) false true true true 2021 true true true false true false GOLD 2026-08-02 true https://doi.org/10.1016/j.esmoop.2021.100106 16 0 16 8 0 15 16 15 15 16 16 8 8 8 8 0 16 8 16 8 0 4 4 Folyóiratcikk Journal Article 24 15 Könyvrészlet Chapter in Book 25 1 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2021 0 2 0 2 0 2022 0 3 2 3 2 2023 0 4 2 4 2 2024 0 1 1 1 1 2025 0 2 2 2 2 2026 0 4 1 4 1 Q1 false false false false 2021-07-09T09:49:56.269+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 3 21 1 34 0 true 10003133 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96275931 /api/authorship/96275931 de Guillebon, E. 1 0.0 true false false de Guillebon E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275932 /api/authorship/96275932 Jimenez, M. 2 0.0 false false false Jimenez M. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275933 /api/authorship/96275933 Mazzarella, L. 3 0.0 false false false Mazzarella L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275934 /api/authorship/96275934 Betsou, F. 4 0.0 false false false Betsou F. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275935 /api/authorship/96275935 Stadler, P. 5 0.0 false false false Stadler P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275936 /api/authorship/96275936 Peták, I. [Peták, István (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 6 0.0 false false false Author 10040839 /api/author/10040839 Peták István (farmakológia) Peták István true 10040839 true Peták I. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275937 /api/authorship/96275937 Jeannot, E. 7 0.0 false false false Jeannot E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275938 /api/authorship/96275938 Chanas, L. 8 0.0 false false false Chanas L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275939 /api/authorship/96275939 Servant, N. 9 0.0 false false false Servant N. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275940 /api/authorship/96275940 Marret, G. 10 0.0 false false false Marret G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275941 /api/authorship/96275941 Duso, B.A. 11 0.0 false false false Duso B.A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275942 /api/authorship/96275942 Legrand, F. 12 0.0 false false false Legrand F. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275943 /api/authorship/96275943 Kornerup, K.N. 13 0.0 false false false Kornerup K.N. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275944 /api/authorship/96275944 Bernhart, S.H. 14 0.0 false false false Bernhart S.H. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275945 /api/authorship/96275945 Balogh, G. 15 0.0 false false false Balogh G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275946 /api/authorship/96275946 Dóczi, R. [Dóczi, Róbert (Növényi molekulár...), szerző] 16 0.0 false false false Author 10012376 /api/author/10012376 Dóczi Róbert (Növényi molekuláris biológia) Dóczi Róbert true 10012376 true Dóczi R. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275947 /api/authorship/96275947 Filotás, P. 17 0.0 false false false Filotás P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275948 /api/authorship/96275948 Curigliano, G. 18 0.0 false false false Curigliano G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275949 /api/authorship/96275949 Bièche, I. 19 0.0 false false false Bièche I. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275950 /api/authorship/96275950 Guérin, J. 20 0.0 false false false Guérin J. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275951 /api/authorship/96275951 Dirner, A. [Dirner, Anna (molekuláris onkol...), szerző] 21 0.0 false false false Author 10089485 /api/author/10089485 Dirner Anna (molekuláris onkológia) Dirner Anna true true Dirner A. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275952 /api/authorship/96275952 Neuzillet, C. 22 0.0 false false false Neuzillet C. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275953 /api/authorship/96275953 Girard, N. 23 0.0 false false false Girard N. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275954 /api/authorship/96275954 Borcoman, E. 24 0.0 false false false Borcoman E. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275955 /api/authorship/96275955 Larbi Chérif, L. 25 0.0 false false false Larbi Chérif L. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275956 /api/authorship/96275956 Tresca, P. 26 0.0 false false false Tresca P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275957 /api/authorship/96275957 Roufai, D.B. 27 0.0 false false false Roufai D.B. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275958 /api/authorship/96275958 Dupain, C. 28 0.0 false false false Dupain C. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275959 /api/authorship/96275959 Scholl, S. 29 0.0 false false false Scholl S. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275960 /api/authorship/96275960 André, F. 30 0.0 false false false André F. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275961 /api/authorship/96275961 Fernandez, X. 31 0.0 false false false Fernandez X. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275962 /api/authorship/96275962 Filleron, T. 32 0.0 false false false Filleron T. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275963 /api/authorship/96275963 Kamal, M.** ✉ 33 0.0 false true true Kamal M. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96275964 /api/authorship/96275964 Le Tourneau, C. ✉ 34 0.0 false true true Le Tourneau C. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 18775321 /api/publicationidentifier/18775321 DOI: 10.1016/j.esmoop.2021.100106 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.esmoop.2021.100106 https://doi.org/10.1016/j.esmoop.2021.100106 false true PublicationIdentifier 19003542 /api/publicationidentifier/19003542 WoS: 000663044500006 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000663044500006 https://www.webofscience.com/wos/woscc/full-record/000663044500006 false true PublicationIdentifier 19003539 /api/publicationidentifier/19003539 Scopus: 85108741930 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85108741930 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85108741930 true true PublicationIdentifier 18870553 /api/publicationidentifier/18870553 PubMed: 33865192 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 33865192 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33865192&dopt=Abstract false true SjrRating 11197063 /api/sjrrating/11197063 sjr:Q1 (2021) Scopus - Cancer Research ESMO OPEN 2059-7029 49 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1306 /api/classificationexternal/1306 Scopus - Cancer Research true 1306 true Q1 DIRECT true true Reference 20439705 /api/reference/20439705 1. Doebele 2020: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials, Lancet Oncol, 21, p. 271, DOI: 10.1016/S1470-2045(19)30691-6 1 10.1016/S1470-2045(19)30691-6 false true Reference 20439706 /api/reference/20439706 2. Marabelle 2020: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study, Lancet Oncol, 21, p. 1353, DOI: 10.1016/S1470-2045(20)30445-9 2 10.1016/S1470-2045(20)30445-9 false true Reference 20439707 /api/reference/20439707 3. Le Tourneau 2015: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial, Lancet Oncol, 16, p. 1324, DOI: 10.1016/S1470-2045(15)00188-6 3 10.1016/S1470-2045(15)00188-6 false true Reference 20439708 /api/reference/20439708 4. Massard 2017: High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial, Cancer Discov, 7, p. 586, DOI: 10.1158/2159-8290.CD-16-1396 4 10.1158/2159-8290.CD-16-1396 false true Reference 20439709 /api/reference/20439709 5. Rodon 2019: Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial, Nat Med, 25, p. 751, DOI: 10.1038/s41591-019-0424-4 5 10.1038/s41591-019-0424-4 false true Reference 20439710 /api/reference/20439710 6. Dotto 2016: Squamous cell cancers: a unified perspective on biology and genetics, Cancer Cell, 29, p. 622, DOI: 10.1016/j.ccell.2016.04.004 6 10.1016/j.ccell.2016.04.004 false true Reference 20439711 /api/reference/20439711 7. Brahmer 2015: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, p. 123, DOI: 10.1056/NEJMoa1504627 7 10.1056/NEJMoa1504627 false true Reference 20439712 /api/reference/20439712 8. Morris 2017: Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, p. 446, DOI: 10.1016/S1470-2045(17)30104-3 8 10.1016/S1470-2045(17)30104-3 false true Reference 20439713 /api/reference/20439713 9. Ferris 2016: Nivolumab for recurrent squamous-cell carcinoma of the head and neck, N Engl J Med, 375, p. 1856, DOI: 10.1056/NEJMoa1602252 9 10.1056/NEJMoa1602252 false true Reference 20439714 /api/reference/20439714 10. Frenel 2017: Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial, J Clin Oncol, 35, p. 4035, DOI: 10.1200/JCO.2017.74.5471 10 10.1200/JCO.2017.74.5471 false true Reference 20439715 /api/reference/20439715 11. Pons-Tostivint 2019: Comparative analysis of durable responses on immune checkpoint inhibitors versus other systemic therapies: a pooled analysis of phase III trials, JCO Precis Oncol, 3, p. 1 11 false true Reference 20439716 /api/reference/20439716 12. Aspeslagh 2018: Epigenetic modifiers as new immunomodulatory therapies in solid tumours, Ann Oncol, 29, p. 812, DOI: 10.1093/annonc/mdy050 12 10.1093/annonc/mdy050 false true Reference 20439717 /api/reference/20439717 13. 2012: Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, p. 519, DOI: 10.1038/nature11404 13 10.1038/nature11404 false true Reference 20439718 /api/reference/20439718 14. 2015: Comprehensive genomic characterization of head and neck squamous cell carcinomas, Nature, 517, p. 576, DOI: 10.1038/nature14129 14 10.1038/nature14129 false true Reference 20439719 /api/reference/20439719 15. 2017: Integrated genomic and molecular characterization of cervical cancer, Nature, 543, p. 378, DOI: 10.1038/nature21386 15 10.1038/nature21386 false true Reference 20439720 /api/reference/20439720 16. Hoadley 2018: Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer, Cell, 173, p. 291, DOI: 10.1016/j.cell.2018.03.022 16 10.1016/j.cell.2018.03.022 false true Reference 20439721 /api/reference/20439721 17. Scholl 2019: Clinical and genetic landscape of treatment naive cervical cancer: alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome, EbioMedicine, 43, p. 253, DOI: 10.1016/j.ebiom.2019.03.069 17 10.1016/j.ebiom.2019.03.069 false true Reference 20439722 /api/reference/20439722 18. Campbell 2018: Genomic, pathway network, and immunologic features distinguishing squamous carcinomas, Cell Rep, 23, p. 194, DOI: 10.1016/j.celrep.2018.03.063 18 10.1016/j.celrep.2018.03.063 false true Reference 20439723 /api/reference/20439723 19. Li 2019: The immune subtypes and landscape of squamous cell carcinoma, Clin Cancer Res, 25, p. 3528 19 false true Reference 20439724 /api/reference/20439724 20. Ott 2019: T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028, J Clin Oncol, 37, p. 318, DOI: 10.1200/JCO.2018.78.2276 20 10.1200/JCO.2018.78.2276 false true Reference 20439725 /api/reference/20439725 21. Trafalis 2018: Evidence for efficacy of treatment with the anti-PD-1 mab nivolumab in radiation and multichemorefractory advanced penile squamous cell carcinoma, J Immunother, 41, p. 300 21 false true Reference 20439726 /api/reference/20439726 22. Burtness 2019: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study, Lancet, 394, p. 1915, DOI: 10.1016/S0140-6736(19)32591-7 22 10.1016/S0140-6736(19)32591-7 false true Reference 20439727 /api/reference/20439727 23. Cohen 2019: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, Lancet, 393, p. 156, DOI: 10.1016/S0140-6736(18)31999-8 23 10.1016/S0140-6736(18)31999-8 false true Reference 20439728 /api/reference/20439728 24. Bauml 2017: Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study, J Clin Oncol, 35, p. 1542, DOI: 10.1200/JCO.2016.70.1524 24 10.1200/JCO.2016.70.1524 false true Reference 20439729 /api/reference/20439729 25. Seiwert 2016: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial, Lancet Oncol, 17, p. 956, DOI: 10.1016/S1470-2045(16)30066-3 25 10.1016/S1470-2045(16)30066-3 false true Reference 20439730 /api/reference/20439730 26. Mehra 2018: Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012, Br J Cancer, 119, p. 153, DOI: 10.1038/s41416-018-0131-9 26 10.1038/s41416-018-0131-9 false true Reference 20439731 /api/reference/20439731 27. Colevas 2018: Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial, Ann Oncol, 29, p. 2247, DOI: 10.1093/annonc/mdy411 27 10.1093/annonc/mdy411 false true Reference 20439732 /api/reference/20439732 28. Ferris 2020: Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study, Ann Oncol, 31, p. 942, DOI: 10.1016/j.annonc.2020.04.001 28 10.1016/j.annonc.2020.04.001 false true Reference 20439733 /api/reference/20439733 29. Zandberg 2019: Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy, Eur J Cancer, 107, p. 142, DOI: 10.1016/j.ejca.2018.11.015 29 10.1016/j.ejca.2018.11.015 false true Reference 20439734 /api/reference/20439734 30. Siu 2019: Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial, JAMA Oncol, 5, p. 195, DOI: 10.1001/jamaoncol.2018.4628 30 10.1001/jamaoncol.2018.4628 false true Reference 20439735 /api/reference/20439735 31. Segal 2019: Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort, Eur J Cancer, 109, p. 154, DOI: 10.1016/j.ejca.2018.12.029 31 10.1016/j.ejca.2018.12.029 false true Reference 20439736 /api/reference/20439736 32. Naumann 2019: Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial, J Clin Oncol, 37, p. 2825, DOI: 10.1200/JCO.19.00739 32 10.1200/JCO.19.00739 false true Reference 20439737 /api/reference/20439737 33. Rizvi 2015: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, p. 124, DOI: 10.1126/science.aaa1348 33 10.1126/science.aaa1348 false true Reference 20439738 /api/reference/20439738 34. Galvis 2020: Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: a systematic review and meta-analysis, Crit Rev Oncol Hematol, 150, p. 102966, DOI: 10.1016/j.critrevonc.2020.102966 34 10.1016/j.critrevonc.2020.102966 false true Reference 20439739 /api/reference/20439739 35. Wang 2019: HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma, Sci Rep, 9, p. 13404, DOI: 10.1038/s41598-019-49771-0 35 10.1038/s41598-019-49771-0 false true Reference 20439740 /api/reference/20439740 36. Roy 2014: Driver mutations of cancer epigenomes, Protein Cell, 5, p. 265, DOI: 10.1007/s13238-014-0031-6 36 10.1007/s13238-014-0031-6 false true Reference 20439741 /api/reference/20439741 37. Gatti 2019: ΔNp63 in squamous cell carcinoma: defining the oncogenic routes affecting epigenetic landscape and tumour microenvironment, Mol Oncol, 13, p. 981, DOI: 10.1002/1878-0261.12473 37 10.1002/1878-0261.12473 false true Reference 20439742 /api/reference/20439742 38. Ford 2015: The cancer COMPASS: navigating the functions of MLL complexes in cancer, Cancer Genet, 208, p. 178, DOI: 10.1016/j.cancergen.2015.01.005 38 10.1016/j.cancergen.2015.01.005 false true Reference 20439743 /api/reference/20439743 39. Morel 2020: Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise, Nat Rev Clin Oncol, 17, p. 91, DOI: 10.1038/s41571-019-0267-4 39 10.1038/s41571-019-0267-4 false true Reference 20439744 /api/reference/20439744 40. Arenas-Ramirez 2018: Epigenetic mechanisms of tumor resistance to immunotherapy, Cell Mol Life Sci, 75, p. 4163, DOI: 10.1007/s00018-018-2908-7 40 10.1007/s00018-018-2908-7 false true Reference 20439745 /api/reference/20439745 41. Woods 2015: HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade, Cancer Immunol Res, 3, p. 1375, DOI: 10.1158/2326-6066.CIR-15-0077-T 41 10.1158/2326-6066.CIR-15-0077-T false true Reference 20439746 /api/reference/20439746 42. Pauken 2016: Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade, Science, 354, p. 1160, DOI: 10.1126/science.aaf2807 42 10.1126/science.aaf2807 false true Reference 20439747 /api/reference/20439747 43. Falkenberg 2014: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders, Nat Rev Drug Discov, 13, p. 673, DOI: 10.1038/nrd4360 43 10.1038/nrd4360 false true Reference 20439748 /api/reference/20439748 44. Adeegbe 2017: Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer, Cancer Discov, 7, p. 852, DOI: 10.1158/2159-8290.CD-16-1020 44 10.1158/2159-8290.CD-16-1020 false true Reference 20439749 /api/reference/20439749 45. Tesone 2016: Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells, Cell Rep, 14, p. 1774, DOI: 10.1016/j.celrep.2016.01.056 45 10.1016/j.celrep.2016.01.056 false true Reference 20439750 /api/reference/20439750 46. Llopiz 2018: The HDAC inhibitor belinostat enhances the anti-tumor efficacy of immune checkpoint inhibitors in a murine hepatocellular carcinoma model, J Hepatol, 68, p. S677, DOI: 10.1016/S0168-8278(18)31612-X 46 10.1016/S0168-8278(18)31612-X false true Reference 20439751 /api/reference/20439751 47. Orillion 2017: Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma, Clin Cancer Res, 23, p. 5187, DOI: 10.1158/1078-0432.CCR-17-0741 47 10.1158/1078-0432.CCR-17-0741 false true Reference 20439752 /api/reference/20439752 48. Guerriero 2017: Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages, Nature, 543, p. 428, DOI: 10.1038/nature21409 48 10.1038/nature21409 false true Reference 20439753 /api/reference/20439753 49. Gray 2019: Phase I/Ib study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer, Clin Cancer Res, 25, p. 6623, DOI: 10.1158/1078-0432.CCR-19-1305 49 10.1158/1078-0432.CCR-19-1305 false true Reference 20439754 /api/reference/20439754 50. Saltos 2020: Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC), J Clin Oncol, 38, p. 9567, DOI: 10.1200/JCO.2020.38.15_suppl.9567 50 10.1200/JCO.2020.38.15_suppl.9567 false true Reference 20439755 /api/reference/20439755 51. Rodriguez 2020: A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer, Clin Cancer Res, 26, p. 837, DOI: 10.1158/1078-0432.CCR-19-2214 51 10.1158/1078-0432.CCR-19-2214 false true Reference 20439756 /api/reference/20439756 52. Gandhi 2018: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy, J Clin Oncol, 36, p. 9036, DOI: 10.1200/JCO.2018.36.15_suppl.9036 52 10.1200/JCO.2018.36.15_suppl.9036 false true Reference 20439757 /api/reference/20439757 53. Topper 2020: The emerging role of epigenetic therapeutics in immuno-oncology, Nat Rev Clin Oncol, 17, p. 75, DOI: 10.1038/s41571-019-0266-5 53 10.1038/s41571-019-0266-5 false true Reference 20439758 /api/reference/20439758 54. van Vugt 2019: Immunogenicity of pembrolizumab in patients with advanced tumors, J Immunother Cancer, 7, p. 212, DOI: 10.1186/s40425-019-0663-4 54 10.1186/s40425-019-0663-4 false true Reference 20439759 /api/reference/20439759 55. Sullivan 2019: Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy, Cancer Res, 79, p. CT072 55 false true Reference 20439760 /api/reference/20439760 56. DiNardo 2019: Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia, Blood, 133, p. 7, DOI: 10.1182/blood-2018-08-868752 56 10.1182/blood-2018-08-868752 false true Reference 20439761 /api/reference/20439761 57. Dunn 2017: Epigenetics and immunotherapy: the current state of play, Mol Immunol, 87, p. 227, DOI: 10.1016/j.molimm.2017.04.012 57 10.1016/j.molimm.2017.04.012 false true Reference 20439762 /api/reference/20439762 58. Italiano 2018: Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study, Lancet Oncol, 19, p. 649, DOI: 10.1016/S1470-2045(18)30145-1 58 10.1016/S1470-2045(18)30145-1 false true Reference 20439763 /api/reference/20439763 59. Stathis 2016: Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628, Cancer Discov, 6, p. 492, DOI: 10.1158/2159-8290.CD-15-1335 59 10.1158/2159-8290.CD-15-1335 false true Reference 20439764 /api/reference/20439764 60. Voorwerk 2019: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial, Nat Med, 25, p. 920, DOI: 10.1038/s41591-019-0432-4 60 10.1038/s41591-019-0432-4 false true Reference 20439765 /api/reference/20439765 61. Juergens 2011: Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, 1, p. 598, DOI: 10.1158/2159-8290.CD-11-0214 61 10.1158/2159-8290.CD-11-0214 false true /api/publication/32012570 de Guillebon E. et al. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. (2021) ESMO OPEN 2059-7029 2059-7029 6 3<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" >de Guillebon E. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10040839"><a href="/gui2/?type=authors&mode=browse&sel=10040839" target="_blank">Peták I. (<span class="authorship-author-name">Peták István</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10012376"><a href="/gui2/?type=authors&mode=browse&sel=10012376" target="_blank">Dóczi R. (<span class="authorship-author-name">Dóczi Róbert</span> <span class="authorAux-mtmt"> Növényi molekuláris biológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10089485"><a href="/gui2/?type=authors&mode=browse&sel=10089485" target="_blank">Dirner A. (<span class="authorship-author-name">Dirner Anna</span> <span class="authorAux-mtmt"> molekuláris onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; et al. (34) </div> <div><a target="_blank" href="/api/publication/32012570?labelLang=hun">Összes szerző</a></div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32012570" target="_blank">Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial</a></div> <div> <span class="journal-title">ESMO OPEN</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2059-7029">2059-7029</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2059-7029">2059-7029</a>)</span>: <span class="journal-volume">6</span> <span class="journal-issue">3</span> <span class="page"> Paper 100106. 12 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.esmoop.2021.100106" target="_blank" href="https://doi.org/10.1016/j.esmoop.2021.100106"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000663044500006" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000663044500006"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85108741930" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85108741930"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="33865192" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33865192&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cancer Research&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Oncology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 16</span> | Független: 8 | Függő: 8 | Nem jelölt: 0 | WoS jelölt: 15 | Scopus jelölt:&nbsp;15 | WoS/Scopus jelölt:&nbsp;16 | DOI jelölt:&nbsp;16 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32012570&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 4 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32012570</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Sokszerzős vagy csoportos szerzőségű szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (ED_18-2-2019-0001) Támogató: NKFIH, (NVKP_ 16-1-2016-0005) Támogató: NKFIH, (2019-1.1.1-PIACI-KFI-2019-00367) </div> <div class="lastModified">Utolsó módosítás: 2025.06.03. 16:30 Dirner Anna (molekuláris onkológia) </div> <div class="lockedBy">Központi kezelésű 2022.03.25. 10:34 Boros Annamária (MTMT Központi admin) </div> </div></div>